2026-08-05T15:42:55Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/167922024-11-29T08:21:34Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16968

00925njm 22002777a 4500 dc Rose, Angela Mc author Nicolay, Nathalie author Sandonis-Martin, Virginia author Mazagatos, Clara author Petrović, Goranka author Niessen, F Annabel author Machado, Ausenda author Launay, Odile author Denayer, Sarah author Seyler, Lucie author Baruch, Joaquin author Burgui, Cristina author Loghin, Isabela I author Domegan, Lisa author Vaikutytė, Roberta author Husa, Petr author Panagiotakopoulos, George author Aouali, Nassera author Dürrwald, Ralf author Howard, Jennifer author Pozo Sanchez, Francisco author Sastre-Palou, Bartolomé author Nonković, Diana author Knol, Mirjam J author Kislaya, Irina author Luong Nguyen, Liem Binh author Bossuyt, Nathalie author Demuyser, Thomas author Džiugytė, Aušra author Martínez-Baz, Iván author Popescu, Corneliu author Duffy, Róisín author Kuliešė, Monika author Součková, Lenka author Michelaki, Stella author Simon, Marc author Reiche, Janine author Otero-Barrós, María Teresa author Lovrić Makarić, Zvjezdana author Bruijning-Verhagen, Patricia Cjl author Gomez, Verónica author Lesieur, Zineb author Barbezange, Cyril author Van Nedervelde, Els author Borg, Maria-Louise author Castilla, Jesús author Lazar, Mihaela author O'Donnell, Joan author Jonikaitė, Indrė author Demlová, Regina author Amerali, Marina author Wirtz, Gil author Tolksdorf, Kristin author Valenciano, Marta author Bacci, Sabrina author Kissling, Esther author MOVECOVID- 19 hospital study team author VEBIS hospital study team author 2023-11 Introduction: Two large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021. Methods: Forty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset. Results: We included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69-92) overall and 75% (95% CI: 42-90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57-98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; ≥ 70% in those 90-179 days before onset. Conclusions: Our results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%. Euro Surveill. 2023 Nov;28(47):2300186. 10.2807/1560-7917.ES.2023.28.47.2300186 1560-7917 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 37997666 http://hdl.handle.net/20.500.12105/16792 Alpha Delta Europe SARS-CoV-2 Hospital Vaccine effectiveness Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021